ISTA Pharmaceuticals

From WikiMD's WELLNESSPEDIA


Overview[edit]

ISTA Pharmaceuticals was a pharmaceutical company that specialized in the development and commercialization of therapies for diseases and conditions of the eye. The company was known for its focus on ophthalmology and had a range of products aimed at treating various eye disorders.

History[edit]

ISTA Pharmaceuticals was founded with the mission to address unmet medical needs in the field of ophthalmology. Over the years, the company developed a portfolio of products that targeted conditions such as glaucoma, dry eye syndrome, and allergic conjunctivitis.

Products[edit]

ISTA Pharmaceuticals developed several notable products, including:

  • Bromday - A nonsteroidal anti-inflammatory drug (NSAID) used to treat postoperative inflammation and reduce pain in patients who have undergone cataract surgery.
  • Xibrom - Another NSAID indicated for the treatment of inflammation and pain associated with cataract surgery.
  • Vitrase - An enzyme used as a spreading agent to facilitate the dispersion and absorption of other injected drugs.

Acquisition[edit]

In 2012, ISTA Pharmaceuticals was acquired by Bausch + Lomb, a leading global eye health company. This acquisition allowed Bausch + Lomb to expand its portfolio of ophthalmic pharmaceuticals and enhance its research and development capabilities in the field of eye care.

Research and Development[edit]

ISTA Pharmaceuticals was committed to innovation in ophthalmology. The company invested in research and development to create new therapies for eye diseases. Their R&D efforts were focused on improving existing treatments and developing new solutions for conditions such as macular degeneration and diabetic retinopathy.

Impact on Ophthalmology[edit]

The contributions of ISTA Pharmaceuticals to the field of ophthalmology were significant. By providing effective treatments for common eye conditions, the company helped improve the quality of life for many patients. Their focus on eye health and dedication to innovation set a standard in the industry.

Related pages[edit]

Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.org/index.php?title=ISTA_Pharmaceuticals&oldid=6614787"